Table of Contents Author Guidelines Submit a Manuscript
Analytical Cellular Pathology
Volume 2016, Article ID 6074275, 5 pages
http://dx.doi.org/10.1155/2016/6074275
Research Article

VEGF +936 C/T Genetic Polymorphism in Patients with Cervical Dysplasia

11st Clinic of Obstetrics and Gynecology, University of Medicine and Pharmacy “Iuliu Hatieganu”, Clinicilor 3-5, 400006 Cluj-Napoca, Romania
2Department of Economic Sciences, University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca, Calea Manastur 3-5, 400372 Cluj-Napoca, Romania
3Department of Molecular Sciences, University of Medicine and Pharmacy “Iuliu Hatieganu”, Clinicilor 3-5, 400006 Cluj-Napoca, Romania
41st Clinic of Obstetrics and Gynecology, Emergency County Hospital, Cluj-Napoca, Romania

Received 14 June 2016; Accepted 1 September 2016

Academic Editor: Ilary Ruscito

Copyright © 2016 Ioana Cristina Rotar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, vol. 136, no. 5, pp. E359–E386, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. C. B. J. Woodman, S. I. Collins, and L. S. Young, “The natural history of cervical HPV infection: unresolved issues,” Nature Reviews Cancer, vol. 7, no. 1, pp. 11–22, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. M. M. Koeneman, R. F. P. M. Kruitwagen, H. W. Nijman, B. F. M. Slangen, T. Van Gorp, and A.-J. Kruse, “Natural history of high-grade cervical intraepithelial neoplasia: a review of prognostic biomarkers,” Expert Review of Molecular Diagnostics, vol. 15, no. 4, pp. 527–546, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. World Health Organization, WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention, World Health Organization, Geneva, Switzerland, 2013, http://www.who.int/reproductivehealth/publications/cancers/screening_and_treatment_of_precancerous_lesions/en/.
  5. H. zur Hausen, “Papillomaviruses and cancer: from basic studies to clinical application,” Nature Reviews Cancer, vol. 2, no. 5, pp. 342–350, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. J. M. Walboomers, M. V. Jacobs, M. M. Manos et al., “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide,” The Journal of Pathology, vol. 189, no. 1, pp. 12–19, 1999. View at Publisher · View at Google Scholar
  7. D. I. R. Holmes and I. Zachary, “The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease,” Genome Biology, vol. 6, no. 2, article 209, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Vincenti, C. Cassano, M. Rocchi, and M. G. Persico, “Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3,” Circulation, vol. 93, no. 8, pp. 1493–1495, 1996. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Ferrara, H.-P. Gerber, and J. LeCouter, “The biology of VEGF and its receptors,” Nature Medicine, vol. 9, no. 6, pp. 669–676, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. B. J. Monk, L. J. Willmott, and D. A. Sumner, “Anti-angiogenesis agents in metastatic or recurrent cervical cancer,” Gynecologic Oncology, vol. 116, no. 2, pp. 181–186, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Narisawa-Saito and T. Kiyono, “Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins,” Cancer Science, vol. 98, no. 10, pp. 1505–1511, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Toussaint-Smith, D. B. Donner, and A. Roman, “Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors,” Oncogene, vol. 23, no. 17, pp. 2988–2995, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Mandic, S. Usaj Knezevic, and T. Kapicl Ivkovic, “Tissue expression of VEGF in cervical intraepithelial neoplasiaand cervical cancer,” Journal of BUON, vol. 19, pp. 958–964, 2014. View at Google Scholar
  14. E. J. Mayeaux Jr., Modern Colposcopy Textbook and Atlas, Lippincott Williams & Wilkins, 3rd edition, 2012.
  15. D. Solomon, D. Davey, R. Kurman et al., “The 2001 Bethesda System: terminology for reporting results of cervical cytology,” Journal of the American Medical Association, vol. 287, no. 16, pp. 2114–2119, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Rodrigues, J. Furriol, E. Tormo, S. Ballester, A. Lluch, and P. Eroles, “The single-nucleotide polymorphisms +936 C/T VEGF and 2710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population,” Breast Cancer Research and Treatment, vol. 133, no. 2, pp. 769–778, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. B.-C. Kim, W.-Y. Kim, D. Park, W.-H. Chung, K.-S. Shin, and J. Bhak, “SNP@Promoter: a database of human SNPs (Single Nucleotide Polymorphisms) within the putative promoter regions,” BMC Bioinformatics, vol. 9, supplement 1, article S2, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Krippl, U. Langsenlehner, W. Renner et al., “A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk,” International Journal of Cancer, vol. 106, no. 4, pp. 468–471, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Branca, C. Giorgi, M. Ciotti et al., “Down-regulation of E-cadherin is closely associated with progression of cervical intraepithelial neoplasia (CIN), but not with high-risk human papillomavirus (HPV) or disease outcome in cervical cancer,” European Journal of Gynaecological Oncology, vol. 27, no. 3, pp. 215–223, 2006. View at Google Scholar · View at Scopus
  20. I. C. Rotar, D. Muresan, C. Zlatescu, and F. Stamatian, “VEGF and cervical intraepithelial neoplasia: new insights,” Obstetrica si Ginecologia LXIII, vol. 2, pp. 97–102, 2015. View at Google Scholar
  21. R. S. Kerbel, “Tumor angiogenesis,” The New England Journal of Medicine, vol. 358, no. 19, pp. 2039–2049, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. L. J. Willmott and B. J. Monk, “Cervical cancer therapy: current, future and anti-angiogensis targeted treatment,” Expert Review of Anticancer Therapy, vol. 9, no. 7, pp. 895–903, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Nakamura, J. M. Bodily, M. Beglin, S. Kyo, M. Inoue, and L. A. Laimins, “Hypoxia-specific stabilization of HIF-1alpha by human papillomaviruses,” Virology, vol. 387, no. 2, pp. 442–448, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Tomao, A. Papa, L. Rossi et al., “Angiogenesis and antiangiogenic agents in cervical cancer,” OncoTargets and Therapy, vol. 7, pp. 2237–2248, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Bachtiary, E. Selzer, T.-H. Knocke, R. Pötter, and A. Obermair, “Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survival,” Cancer Letters, vol. 179, no. 2, pp. 197–203, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Du, H.-Y. Gong, and Z.-M. Gong, “Influence of serum vegf levels on therapeutic outcome and diagnosis/prognostic value in patients with cervical cancer,” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 20, pp. 8793–8796, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. M.-Z. Wu, Y. Zhang, X. Wu, Z.-M. Fu, G.-P. Wu, and K.-J. Guo, “Transcription expression and clinical significance of mrna of vascular endothelial growth factor and endostatin in liquid-based preparation specimens from patients with cervical dysplasia and carcinoma,” Acta Cytologica, vol. 57, no. 5, pp. 522–527, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. V. Chopra, T. V. Dinh, and E. V. Hannigan, “Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer,” Cancer Investigation, vol. 16, no. 3, pp. 152–159, 1998. View at Publisher · View at Google Scholar · View at Scopus
  29. A. J. Guidi, G. Abu-Jawdeh, B. Berse et al., “Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia,” Journal of the National Cancer Institute, vol. 87, no. 16, pp. 1237–1245, 1995. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Obermair, D. Bancher-Todesca, S. Bilgi et al., “Correlation of vascular endothelial growth factor expression and microvessel density in Cervical Intraepithelial Neoplasia,” Journal of the National Cancer Institute, vol. 89, no. 16, pp. 1212–1217, 1997. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. H. Kim, M. A. Kim, I.-A. Park et al., “VEGF polymorphisms in early cervical cancer susceptibility, angiogenesis, and survival,” Gynecologic Oncology, vol. 119, no. 2, pp. 232–236, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Konac, H. I. Onen, J. Metindir, E. Alp, A. A. Biri, and A. Ekmekci, “Lack of association between -460 C/T and 936 C/T of the vascular endothelial growth factor and angiopoietin-2 exon 4 G/A polymorphisms and ovarian, cervical, and endometrial cancers,” DNA and Cell Biology, vol. 26, no. 7, pp. 453–463, 2007. View at Publisher · View at Google Scholar · View at Scopus